Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855805 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNALPAR3LPAR2CYP4F2 | |
| SCHEMBL5858394 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNALPAR3LPAR2CYP4F2 | |
| SCHEMBL5857277 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNALPAR3LPAR2CYP4F2 | |
| SCHEMBL21068275 | 0.82 | CYP4F2 (0.60) | ALDH1A1LMNALPAR3LPAR2CYP4F2 | |
| SCHEMBL3627972 | 0.81 | MAPT (0.42) | ALDH1A1LMNALPAR3LPAR2CYP4F2 | |
| SCHEMBL5856474 | 0.77 | CYP4F2 (0.42) | ALDH1A1LMNACYP4F2CYP4A11TSHR | |
| SCHEMBL5857558 | 0.77 | CYP4F2 (0.42) | ALDH1A1LMNACYP4F2CYP4A11TSHR | |
| SCHEMBL5855517 | 0.77 | CYP4F2 (0.42) | ALDH1A1LMNACYP4F2CYP4A11TSHR | |
| SCHEMBL5857183 | 0.77 | CYP4F2 (0.42) | ALDH1A1LMNACYP4F2CYP4A11TSHR | |
| SCHEMBL13390688 | 0.77 | ALDH1A1 (0.41) | ALDH1A1LMNALPAR3LPAR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | ALDH1A1 760/4885LMNA 606/4885LPAR3 738/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | ALDH1A1 571/4885LMNA 601/4885LPAR3 957/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | ALDH1A1 557/4885LMNA 636/4885LPAR3 1126/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | ALDH1A1 557/4885LMNA 636/4885LPAR3 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.